Pancreatic Cancer Pipeline Insight
DelveInsight’s, “Pancreatic Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pancreatic Cancer Understanding
Pancreatic Cancer: Overview
Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. Pancreatic tumors are either exocrine or neuroendocrine (endocrine) tumors. This is based on the type of cell they start in. Knowing the type of tumor is important because each type acts differently and responds to different treatments. About 93% of pancreatic cancers are exocrine tumors. The most common type of pancreatic cancer is adenocarcinoma. About 7% of pancreatic tumors are neuroendocrine tumors (pancreatic NETs or PNETs), also called islet cell tumors. They often grow slower than exocrine tumors. A pancreatic tumor can only be seen on an imaging study such as a computed tomography (CT) scan, magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS). Pancreatic cancer treatment depends on the stage of the disease and the patient’s general health.
"Pancreatic Cancer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Pancreatic Cancer.
Pancreatic Cancer Emerging Drugs Chapters
This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pancreatic Cancer Emerging Drugs
CPI-613 (devimistat): Rafael Pharmaceuticals
Rafael’s first-in-class clinical lead compound, CPI-613® (devimistat), targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. It is currently in Phase 3 in first line Pancreatic Cancer and Relapsed/Refractory AML. Additional clinical programs are also currently underway across multiple indications as a single agent, as well as in combination with standard drug therapy. The EMA has granted orphan drug designation to CPI-613® for Pancreatic Cancer and AML. CPI-613® has IP protection and regulatory exclusivity out to 2028 and potentially beyond.
Masitinib: AB Science
Masitinib, AB Science main compound, is a selective tyrosine kinase inhibitor which is currently developed in three therapeutic areas: neurology, inflammatory diseases and oncology. As of today, masitinib is mainly developed in the following indications: amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer disease, mastocytosis, severe asthma, prostate cancer and pancreatic cancer. Masitinib pipeline is well advanced with promising phase 3 data in Amyotrophic Lateral Sclerosis (ALS), indolent severe systemic mastocytosis and severe asthma.
EndoTAG-1: Syncore Biotechnology
EndoTAG-1 (SB05) is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.
Acalabrutinib: Acerta Pharma
Acalabrutinib (ACP-196) is a highly selective, Bruton's tyrosine kinase (BTK) inhibitor developed to minimize off-target activity with minimal effects on TEC, EGFR, or ITK signaling. Acalabrutinib (ACP 196) is an orally administered, second generation, agammaglobulinaemia tyrosine kinase inhibitor. Currently, it is in phase 2 stage of development for the treatment of pancreatic cancer.
SM-88 (racemetyrosine): Tyme Technologies
SM-88 (racemetyrosine) is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. Oral SM-88 has demonstrated meaningful clinical benefit and well tolerated safety profile, in metastatic cancer patients across 15 different types of solid tumors and hematologic cancers. Currently, it is in phase 3 stage of development for the treatment of pancreatic cancer.
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of locally advanced unresectable pancreatic cancer (LAPC), and in Phase 2 clinical development for the treatment of Duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD. Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with IPF and LAPC.
Further product details are provided in the report……..
Pancreatic Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pancreatic Cancer
There are approx. 100+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pancreatic Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.
Pancreatic Cancer Report Insights
- Pancreatic Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Pancreatic Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pancreatic Cancer drugs?
- How many Pancreatic Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pancreatic Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?